Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a 300-page biotech filing isn’t easy—especially when Phio Pharmaceuticals’ disclosures dive deep into RNAi chemistry, IND milestones and financing rounds. If you’ve ever searched the 10-K for cash-runway details or hunted through Form 4s to see when executives buy shares ahead of INTASYL trial data, you know the challenge.
Stock Titan solves that problem. Our AI reads every document the moment it hits EDGAR and delivers plain-English answers to the questions investors actually ask: “Phio Pharmaceuticals SEC filings explained simply” and “understanding Phio Pharmaceuticals SEC documents with AI.” Quickly jump from an “Item 1A-Risk Factors” headline to a one-sentence summary, or set real-time alerts for “Phio Pharmaceuticals Form 4 insider transactions real-time.” You’ll also find:
- Complete Phio Pharmaceuticals annual report 10-K simplified—cash burn, R&D spend and INTASYL pipeline updates distilled by AI.
- Every Phio Pharmaceuticals quarterly earnings report 10-Q filing with side-by-side trend charts.
- Immediate access to Phio Pharmaceuticals 8-K material events explained—from trial results to financing announcements.
- Detailed Phio Pharmaceuticals proxy statement executive compensation breakdowns.
The result: faster insight into PH-762 progress, better tracking of Phio Pharmaceuticals insider trading Form 4 transactions, and the context you need to act decisively. Whether you’re scanning Phio Pharmaceuticals earnings report filing analysis or monitoring Phio Pharmaceuticals executive stock transactions Form 4, our platform keeps you ahead of the curve—without wading through biotech jargon.
Phio Pharmaceuticals (PHIO) amended an insider filing to report a corrected grant of restricted stock units. Director Robert L. Ferrara was granted 23,100 restricted stock units on 09/11/2025 that will convert into common shares when they vest on the first annual anniversary of the grant. Following this grant and existing unvested RSUs, Ferrara beneficially owns 38,766 shares of common stock; the amended filing corrects previously reported counts that understated the grant and total ownership. The amendment also notes that reported share counts were adjusted for prior reverse stock splits.
David H. Deming, a director of Phio Pharmaceuticals Corp. (PHIO), reported an acquisition on 09/11/2025 of 14,000 shares of common stock through restricted stock units (RSUs) with a reported price of $0. The filing states these shares represent units that will vest on the first annual anniversary of the grant and that the 14,000 shares reported include common stock underlying unvested RSUs.
The Form 4 was signed by attorney-in-fact Lisa C. Carson on 09/15/2025. The transaction increases the director’s beneficial ownership by the 14,000 shares subject to future vesting; no cash purchase price was reported in the filing.
Phio Pharmaceuticals (PHIO) director Curtis Lockshin reported an insider grant and updated holdings on Form 4. On 09/11/2025 he was granted 16,200 shares (reported as shares underlying a restricted stock unit) that will vest on the first annual anniversary of the grant; the grant was recorded at a $0 price. After the reported transaction, the filing shows Mr. Lockshin beneficially owns 18,555 shares, which includes shares underlying unvested restricted stock units. The filing notes the reported totals were adjusted for prior reverse stock splits and the Form 4 was signed on 09/15/2025 by an attorney-in-fact.
Phio Pharmaceuticals insider Jonathan E. Freeman reported acquisition of 14,700 shares of common stock on 09/11/2025 through restricted stock units that will vest on the first annual anniversary of the grant. Following the reported transaction Freeman beneficially owns 16,055 shares, a figure that includes other unvested restricted stock units. The filing states the reported amounts were adjusted to reflect prior reverse stock splits. The form was signed by an attorney-in-fact on behalf of the reporting person.
Robert L. Ferrara, a director of Phio Pharmaceuticals Corp. (PHIO), reported acquisition of 23,000 shares of common stock represented by restricted stock units on 09/11/2025. The RSUs vest on the first annual anniversary of the grant and the reported beneficial ownership following the transaction is 38,666 shares, which includes shares underlying unvested RSUs. The filing notes the reported share totals were adjusted for prior reverse stock splits. The disclosure was submitted on a Form 4 by a single reporting person and includes a power of attorney exhibit.
Phio Pharmaceuticals (PHIO) reporting person Lisa C. Carson, who is listed as a director and VP, Finance and Administration, reported a non-derivative acquisition on 09/11/2025. The filing shows 47,000 shares of common stock were acquired at $0, representing shares underlying a restricted stock unit grant. The filing states those shares "will vest on the first annual anniversary of the grant," and that the 47,000 shares reported include common stock underlying unvested restricted stock units. The form is signed 09/15/2025.
Phio Pharmaceuticals Corp. director Patricia A. Bradford reported a change in beneficial ownership related to restricted stock units. The filing shows an acquisition of 18,800 shares of common stock issued to satisfy restricted stock units that will vest on the first annual anniversary of the grant. Following the reported transaction, Ms. Bradford beneficially owns 27,151 shares, a total that the filing indicates includes shares underlying unvested restricted stock units. The reported share counts have been adjusted to reflect prior reverse stock splits. The transaction was reported as an acquisition at $0 per share, consistent with issuance upon vesting of RSUs.
Robert J. Bitterman, Chairman, President and CEO of Phio Pharmaceuticals Corp. (PHIO), reported equity transactions on a Form 4 filed for activity dated 09/11/2025. The filing shows 4,111 shares were withheld by the issuer to satisfy tax withholding related to vested restricted stock units; no shares were sold.
The reporting person was also granted 250,000 restricted stock units on that date that vest on the first annual anniversary of the grant. After these transactions the filing reports 271,421 shares of common stock beneficially owned by Mr. Bitterman. The Form 4 was signed by an attorney-in-fact on 09/15/2025.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
